![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: ANK3 |
Gene summary for ANK3 |
![]() |
Gene information | Species | Human | Gene symbol | ANK3 | Gene ID | 288 |
Gene name | ankyrin 3 | |
Gene Alias | ANKYRIN-G | |
Cytomap | 10q21.2 | |
Gene Type | protein-coding | GO ID | GO:0000278 | UniProtAcc | Q12955 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
288 | ANK3 | CA_HPV_1 | Human | Cervix | CC | 6.30e-03 | -2.39e-01 | 0.0264 |
288 | ANK3 | CCI_1 | Human | Cervix | CC | 6.68e-11 | 1.43e+00 | 0.528 |
288 | ANK3 | CCI_2 | Human | Cervix | CC | 1.57e-20 | 2.22e+00 | 0.5249 |
288 | ANK3 | CCI_3 | Human | Cervix | CC | 1.66e-37 | 2.03e+00 | 0.516 |
288 | ANK3 | CCII_1 | Human | Cervix | CC | 5.77e-03 | 3.56e-01 | 0.3249 |
288 | ANK3 | HTA11_3410_2000001011 | Human | Colorectum | AD | 3.42e-31 | -7.79e-01 | 0.0155 |
288 | ANK3 | HTA11_2487_2000001011 | Human | Colorectum | SER | 2.30e-04 | -4.55e-01 | -0.1808 |
288 | ANK3 | HTA11_3361_2000001011 | Human | Colorectum | AD | 5.21e-20 | -8.78e-01 | -0.1207 |
288 | ANK3 | HTA11_696_2000001011 | Human | Colorectum | AD | 1.95e-29 | -6.31e-01 | -0.1464 |
288 | ANK3 | HTA11_866_2000001011 | Human | Colorectum | AD | 3.63e-07 | -3.70e-01 | -0.1001 |
288 | ANK3 | HTA11_5212_2000001011 | Human | Colorectum | AD | 5.52e-04 | -5.71e-01 | -0.2061 |
288 | ANK3 | HTA11_7862_2000001011 | Human | Colorectum | AD | 2.44e-05 | -5.84e-01 | -0.0179 |
288 | ANK3 | HTA11_866_3004761011 | Human | Colorectum | AD | 8.05e-24 | -7.61e-01 | 0.096 |
288 | ANK3 | HTA11_8622_2000001021 | Human | Colorectum | SER | 9.09e-08 | -7.04e-01 | 0.0528 |
288 | ANK3 | HTA11_10711_2000001011 | Human | Colorectum | AD | 1.24e-07 | -5.69e-01 | 0.0338 |
288 | ANK3 | HTA11_7696_3000711011 | Human | Colorectum | AD | 1.51e-12 | -4.65e-01 | 0.0674 |
288 | ANK3 | HTA11_11156_2000001011 | Human | Colorectum | AD | 1.74e-05 | -9.51e-01 | 0.0397 |
288 | ANK3 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 1.73e-15 | -4.97e-01 | 0.294 |
288 | ANK3 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 8.50e-08 | -3.67e-01 | 0.3859 |
288 | ANK3 | HTA11_99999973899_84307 | Human | Colorectum | MSS | 4.60e-18 | -9.56e-01 | 0.2585 |
Page: 1 2 3 4 5 6 7 8 9 10 11 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:002240710 | Cervix | CC | regulation of cell-cell adhesion | 103/2311 | 448/18723 | 1.78e-10 | 2.87e-08 | 103 |
GO:004578510 | Cervix | CC | positive regulation of cell adhesion | 101/2311 | 437/18723 | 1.96e-10 | 3.08e-08 | 101 |
GO:190382910 | Cervix | CC | positive regulation of cellular protein localization | 72/2311 | 276/18723 | 3.20e-10 | 4.46e-08 | 72 |
GO:007265910 | Cervix | CC | protein localization to plasma membrane | 73/2311 | 284/18723 | 4.95e-10 | 6.73e-08 | 73 |
GO:00512359 | Cervix | CC | maintenance of location | 78/2311 | 327/18723 | 5.18e-09 | 4.92e-07 | 78 |
GO:19907788 | Cervix | CC | protein localization to cell periphery | 78/2311 | 333/18723 | 1.22e-08 | 9.73e-07 | 78 |
GO:005122210 | Cervix | CC | positive regulation of protein transport | 72/2311 | 303/18723 | 2.36e-08 | 1.70e-06 | 72 |
GO:005165110 | Cervix | CC | maintenance of location in cell | 55/2311 | 214/18723 | 6.63e-08 | 3.85e-06 | 55 |
GO:190495110 | Cervix | CC | positive regulation of establishment of protein localization | 73/2311 | 319/18723 | 9.69e-08 | 5.25e-06 | 73 |
GO:000660510 | Cervix | CC | protein targeting | 68/2311 | 314/18723 | 2.17e-06 | 6.55e-05 | 68 |
GO:00903167 | Cervix | CC | positive regulation of intracellular protein transport | 41/2311 | 160/18723 | 3.24e-06 | 8.80e-05 | 41 |
GO:00323868 | Cervix | CC | regulation of intracellular transport | 71/2311 | 337/18723 | 3.70e-06 | 9.74e-05 | 71 |
GO:00331579 | Cervix | CC | regulation of intracellular protein transport | 52/2311 | 229/18723 | 8.16e-06 | 1.88e-04 | 52 |
GO:00224099 | Cervix | CC | positive regulation of cell-cell adhesion | 61/2311 | 284/18723 | 9.30e-06 | 2.11e-04 | 61 |
GO:00615647 | Cervix | CC | axon development | 89/2311 | 467/18723 | 1.71e-05 | 3.27e-04 | 89 |
GO:00325077 | Cervix | CC | maintenance of protein location in cell | 21/2311 | 65/18723 | 2.03e-05 | 3.71e-04 | 21 |
GO:003410910 | Cervix | CC | homotypic cell-cell adhesion | 26/2311 | 90/18723 | 2.12e-05 | 3.82e-04 | 26 |
GO:19054778 | Cervix | CC | positive regulation of protein localization to membrane | 29/2311 | 106/18723 | 2.29e-05 | 4.01e-04 | 29 |
GO:00323889 | Cervix | CC | positive regulation of intracellular transport | 46/2311 | 202/18723 | 2.45e-05 | 4.24e-04 | 46 |
GO:00988767 | Cervix | CC | vesicle-mediated transport to the plasma membrane | 34/2311 | 136/18723 | 3.75e-05 | 5.91e-04 | 34 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0520516 | Cervix | CC | Proteoglycans in cancer | 60/1267 | 205/8465 | 9.13e-08 | 1.18e-06 | 7.00e-07 | 60 |
hsa0520517 | Cervix | CC | Proteoglycans in cancer | 60/1267 | 205/8465 | 9.13e-08 | 1.18e-06 | 7.00e-07 | 60 |
hsa05205 | Colorectum | AD | Proteoglycans in cancer | 70/2092 | 205/8465 | 1.37e-03 | 8.46e-03 | 5.39e-03 | 70 |
hsa052051 | Colorectum | AD | Proteoglycans in cancer | 70/2092 | 205/8465 | 1.37e-03 | 8.46e-03 | 5.39e-03 | 70 |
hsa052052 | Colorectum | SER | Proteoglycans in cancer | 58/1580 | 205/8465 | 4.37e-04 | 3.82e-03 | 2.77e-03 | 58 |
hsa052053 | Colorectum | SER | Proteoglycans in cancer | 58/1580 | 205/8465 | 4.37e-04 | 3.82e-03 | 2.77e-03 | 58 |
hsa052054 | Colorectum | MSS | Proteoglycans in cancer | 65/1875 | 205/8465 | 8.66e-04 | 5.38e-03 | 3.29e-03 | 65 |
hsa052055 | Colorectum | MSS | Proteoglycans in cancer | 65/1875 | 205/8465 | 8.66e-04 | 5.38e-03 | 3.29e-03 | 65 |
hsa052056 | Colorectum | FAP | Proteoglycans in cancer | 57/1404 | 205/8465 | 3.05e-05 | 3.29e-04 | 2.00e-04 | 57 |
hsa052057 | Colorectum | FAP | Proteoglycans in cancer | 57/1404 | 205/8465 | 3.05e-05 | 3.29e-04 | 2.00e-04 | 57 |
hsa0520518 | Endometrium | AEH | Proteoglycans in cancer | 53/1197 | 205/8465 | 5.43e-06 | 6.53e-05 | 4.78e-05 | 53 |
hsa0520519 | Endometrium | AEH | Proteoglycans in cancer | 53/1197 | 205/8465 | 5.43e-06 | 6.53e-05 | 4.78e-05 | 53 |
hsa0520524 | Endometrium | EEC | Proteoglycans in cancer | 52/1237 | 205/8465 | 3.01e-05 | 3.19e-04 | 2.38e-04 | 52 |
hsa0520534 | Endometrium | EEC | Proteoglycans in cancer | 52/1237 | 205/8465 | 3.01e-05 | 3.19e-04 | 2.38e-04 | 52 |
hsa0520529 | Esophagus | ESCC | Proteoglycans in cancer | 138/4205 | 205/8465 | 1.79e-07 | 1.40e-06 | 7.15e-07 | 138 |
hsa0520537 | Esophagus | ESCC | Proteoglycans in cancer | 138/4205 | 205/8465 | 1.79e-07 | 1.40e-06 | 7.15e-07 | 138 |
hsa0520510 | Liver | Cirrhotic | Proteoglycans in cancer | 85/2530 | 205/8465 | 2.37e-04 | 1.58e-03 | 9.75e-04 | 85 |
hsa0520511 | Liver | Cirrhotic | Proteoglycans in cancer | 85/2530 | 205/8465 | 2.37e-04 | 1.58e-03 | 9.75e-04 | 85 |
hsa0520521 | Liver | HCC | Proteoglycans in cancer | 121/4020 | 205/8465 | 5.22e-04 | 2.18e-03 | 1.21e-03 | 121 |
hsa0520531 | Liver | HCC | Proteoglycans in cancer | 121/4020 | 205/8465 | 5.22e-04 | 2.18e-03 | 1.21e-03 | 121 |
Page: 1 2 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ANK3 | SNV | Missense_Mutation | novel | c.2396N>T | p.Ala799Val | p.A799V | Q12955 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-VQ-A8PO-01 | Stomach | stomach adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
ANK3 | SNV | Missense_Mutation | novel | c.7343N>G | p.Tyr2448Cys | p.Y2448C | Q12955 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.921) | TCGA-VQ-A91D-01 | Stomach | stomach adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | fluorouracil | PD |
ANK3 | SNV | Missense_Mutation | novel | c.2764N>C | p.Ser922Pro | p.S922P | Q12955 | protein_coding | deleterious(0.01) | probably_damaging(0.994) | TCGA-VQ-A91E-01 | Stomach | stomach adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | fluorouracil | CR |
ANK3 | insertion | Frame_Shift_Ins | novel | c.832_833insA | p.Arg278LysfsTer16 | p.R278Kfs*16 | Q12955 | protein_coding | TCGA-CG-4465-01 | Stomach | stomach adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | cisplatin | SD | ||
ANK3 | deletion | Frame_Shift_Del | c.76delN | p.Arg26GlyfsTer21 | p.R26Gfs*21 | Q12955 | protein_coding | TCGA-CG-5723-01 | Stomach | stomach adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |||
ANK3 | deletion | Frame_Shift_Del | c.4931delN | p.Pro1644LeufsTer27 | p.P1644Lfs*27 | Q12955 | protein_coding | TCGA-CG-5726-01 | Stomach | stomach adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |||
ANK3 | deletion | Frame_Shift_Del | novel | c.13099_13100delNN | p.Glu4367AsnfsTer27 | p.E4367Nfs*27 | Q12955 | protein_coding | TCGA-HF-A5NB-01 | Stomach | stomach adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | fluorouracil | SD | ||
ANK3 | insertion | Frame_Shift_Ins | novel | c.6422_6423insC | p.Gln2142ThrfsTer4 | p.Q2142Tfs*4 | Q12955 | protein_coding | TCGA-HU-A4G8-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Chemotherapy | 5-fluorouracil | SD | ||
ANK3 | deletion | Frame_Shift_Del | c.76delA | p.Arg26GlyfsTer21 | p.R26Gfs*21 | Q12955 | protein_coding | TCGA-HU-A4GX-01 | Stomach | stomach adenocarcinoma | Female | >=65 | III/IV | Chemotherapy | taxol | SD | |||
ANK3 | deletion | Frame_Shift_Del | c.188delA | p.Asn63MetfsTer13 | p.N63Mfs*13 | Q12955 | protein_coding | TCGA-VQ-A8P2-01 | Stomach | stomach adenocarcinoma | Male | >=65 | III/IV | Unspecific | Complete Response |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |